Detalhe da pesquisa
1.
Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study.
Cancer
; 130(8): 1281-1291, 2024 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-38261521
2.
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 402(10415): 1835-1847, 2023 11 18.
Artigo
Inglês
| MEDLINE | ID: mdl-37871608
3.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Lancet
; 402(10408): 1133-1146, 2023 09 30.
Artigo
Inglês
| MEDLINE | ID: mdl-37499670
4.
Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Oncology
; 102(4): 318-326, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-37778345
5.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(12): 1399-1410, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-38039993
6.
Transcriptomic alterations underlying metaplasia into specific metaplastic components in metaplastic breast carcinoma.
Breast Cancer Res
; 25(1): 11, 2023 01 27.
Artigo
Inglês
| MEDLINE | ID: mdl-36707876
7.
Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer.
Br J Cancer
; 128(1): 102-111, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36319846
8.
Selective inhibition of HDAC6 promotes bladder cancer radiosensitization and mitigates the radiation-induced CXCL1 signalling.
Br J Cancer
; 128(9): 1753-1764, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36810912
9.
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
J Hepatol
; 78(1): 133-141, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36341767
10.
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
N Engl J Med
; 382(20): 1894-1905, 2020 05 14.
Artigo
Inglês
| MEDLINE | ID: mdl-32402160
11.
Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.
Breast Cancer Res Treat
; 201(3): 377-385, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37344660
12.
Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma.
Eur Radiol
; 33(1): 512-522, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-35864351
13.
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).
Future Oncol
; 19(38): 2505-2516, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37671641
14.
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(8): 995-1008, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35798016
15.
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Lancet Oncol
; 23(1): 77-90, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34914889
16.
Soft tissue sarcoma incidences and clinical characteristics are significantly different in France and Taiwan.
Cancer
; 128(18): 3360-3369, 2022 09 15.
Artigo
Inglês
| MEDLINE | ID: mdl-35796499
17.
Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma.
Br J Cancer
; 126(12): 1806-1814, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35236936
18.
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade.
Br J Cancer
; 126(4): 569-575, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34621044
19.
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
J Hepatol
; 76(4): 862-873, 2022 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-34902530
20.
Cyclin-Dependent Kinase 9 Inhibition as a Potential Treatment for Hepatocellular Carcinoma.
Oncology
; 100(11): 602-611, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36103810